Italia markets close in 3 hours 9 minutes

PFE Mar 2025 29.000 call

OPR - OPR Prezzo differito. Valuta in USD.
Aggiungi a watchlist
2,19000,0000 (0,00%)
In data: 03:56PM EDT. Mercato aperto.
Schermo intero
Chiusura precedente2,1900
Aperto2,1000
Denaro0,0000
Domanda0,0000
Prezzo d'esercizio29,00
Scadenza2025-03-21
Min-Max giorno2,1000 - 2,1900
Contratto - Min-MaxN/D
Volume12
Open Interest1,47k
  • GlobeNewswire

    Arvinas and Pfizer Announce Upcoming Vepdegestrant (ARV-471) Poster Presentation at ESMO Congress 2023

    NEW HAVEN, Conn. and NEW YORK, Oct. 15, 2023 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced they will present updated Phase 1/2 data for vepdegestrant (ARV-471) at the 2023 European Society for Medical Oncology (ESMO) Annual Congress. Vepdegestrant is a novel oral PROTAC® estrogen receptor (ER) degrader that is being jointly developed by Arvinas and Pfizer for the treatment of patients with locally advanced or metastatic ER positive/human epidermal g